Improving T-cell Detection with Protein Kinase Inhibitors
Author Information
Author(s): Lissina Anna, Ladell Kristin, Skowera Ania, Clement Matthew, Edwards Emily, Seggewiss Ruth, van den Berg Hugo A., Gostick Emma, Gallagher Kathleen, Jones Emma, Melenhorst J. Joseph, Godkin Andrew J., Peakman Mark, Price David A., Sewell Andrew K., Wooldridge Linda
Primary Institution: Cardiff University School of Medicine
Hypothesis
Can protein kinase inhibitors enhance the detection of T-cells using peptide-MHC tetramers?
Conclusion
Dasatinib significantly improves the staining intensity of T-cells with peptide-MHC tetramers and allows for the detection of low-affinity T-cells that are typically undetectable.
Supporting Evidence
- Dasatinib treatment resulted in a greater than 10-fold increase in pMHCI tetramer staining intensity.
- Pre-incubation with dasatinib enhanced staining efficiency with all variant pMHCI tetramers.
- Dasatinib treatment reduced pMHCI tetramer-induced cell death.
- Dasatinib allowed the identification of low avidity antigen-specific CD8+ T-cells directly ex vivo.
Takeaway
This study shows that a drug called dasatinib helps scientists see more T-cells by making them easier to spot with special markers, even if those T-cells are usually hard to find.
Methodology
The study involved treating T-cells with dasatinib and measuring the intensity of staining with peptide-MHC tetramers using flow cytometry.
Limitations
The study primarily focuses on the effects of dasatinib and may not address other potential methods for enhancing T-cell detection.
Participant Demographics
Included adult patients with type 1 diabetes and healthy HLA A2-matched control subjects.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website